Macrophage Polarization States in the Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 147 of the 148 references it cites were found in a registry or an index.
Abstract
The M1/M2 macrophage paradigm plays a key role in tumor progression. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The tumor microenvironment (TME) can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes. Investigating TME-induced macrophage polarization is critical for further understanding of TAM-related pro-tumor outcomes and potential development of new therapeutic approaches. This review explores the current understanding of TME-induced macrophage polarization and the role of M2-polarized macrophages in promoting tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that MSCs have the ability to polarize M1 pro-inflammatory macrophages towards an alternative M2 anti-inflammatory phenotype [21,22,23].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, CD4+ T cells impact cancer immunology (30), M1 macrophages suppress tumors, and M2 macrophages aid tumor growth (31).”
From A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer (2025) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, CD4+ T cells impact cancer immunology (30), M1 macrophages suppress tumors, and M2 macrophages aid tumor growth (31).”
From A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer (2025) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 3×
“These CD8+ T and NK cells express high levels of cytokines such as IFN-γ, GM-CSF, and TNF-α as well as chemokines such as CCL4, CCL5, and CCL23 that assist in the further recruitment of immune cells and the signaling of anti-tumorigenic pathways [73,74].”
BackgroundMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 2×
“MDSCs express high levels of both iNOS and arginase-1, which both play a direct role in suppression of T-cell function [95].”
BackgroundOrigin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 1×
“Inflammation can be triggered by conditions such as infection or injury or can be systemic as seen in type 2 diabetes and cardiovascular disease [59].”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 3×
“Current literature supports the theory that most TAMs originate from either tissueresident embryonic macrophages or macrophages derived from circulating monocytes that originate in the bone marrow [87].”
BackgroundMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 3×
“The significance of macrophage heterogeneity has been under review since the early 2000s and has been linked to many malignancies and autoimmune disorders in recent years [66].”
BackgroundProtective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 1×
“The resolution of inflammation is led by the deactivation of these inflammatory mediators, permitting either the apoptosis of pro-inflammatory M1 macrophages or the transition to an anti-inflammatory M2 macrophage [64].”
BackgroundMacrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684 · cited 15×
“Macrophages are found in every human tissue in the body and exhibit anatomical and functional diversity [4].”
BackgroundInfluentialMurray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981 · cited 2×
“Some noncytokine, extrinsic pathways of macrophage polarization do exist, however, including hypoxia as well as the production of lactate within tumors, which drive M2 polarization [36].”
BackgroundFibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Cited by
Items 501–600 of 1,000
Zheng, S., He, H., Zheng, J., Zhu, X., Lin, N., Wu, Q. H., Wei, E., Weng, C., Chen, S., Huang, X., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68706-y · Cited by 22
Zhou, J., Su, S., Xu, J., Yan, T., He, Y., Zhang, L., Liu, C., Zhang, Y., Liu, Y., & Ye, Q. (2024) · Composites Part B Engineering · doi:10.1016/j.compositesb.2024.111811 · Cited by 16
Recent progress in molecular classification of phaeochromocytoma and paraganglioma
Boehm, E., Gill, A. J., Clifton-Bligh, R. J., & Tothill, R. W. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101939 · Cited by 15
Pharmacological potential of natural medicine Astragali Radix in treating intestinal diseases
Wei, X., Leng, X., Liang, J., Liu, J., Chi, L., Deng, H., & Sun, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117580 · Cited by 17
Cómitre-Mariano, B., Vellila-Alonso, G., Segura‐Collar, B., Mondéjar-Ruescas, L., Sepúlveda-Sánchez, J. M., & Gargini, R. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03298-y · Cited by 16
“Macrophages either reside permanently in specific organs (e.g., microglia in the brain, Kupffer cells in the liver, alveolar macrophages in the lungs) or infiltrate tissues as monocytic precursors from the bone marrow, differentiating and maturing in response to cytokines and growth factors [22].”
Dissecting metabolic landscape of alveolar macrophage
Malla, S., Sajeevan, K. A., Acharya, B., Chowdhury, R., & Saha, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-81253-w · Cited by 18
The role of macrophages in liver metastasis: mechanisms and therapeutic prospects
Yuan, Q., Jia, L., Yang, J., & Li, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1542197 · Cited by 21
“This is often linked to a poorer clinical prognosis in patients with liver metastatic cancers (6).”
Liao, L., Wang, Y., Fan, S.-S., Hu, Y., Wang, X.-C., & Zhang, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1571583 · Cited by 18
“…considered to exhibit pro-in fl ammatory and anti-tumor effects, expressing in fl ammatory factors such as interleukin (IL)-1 b , IL-6, and TNF-a (14, 18 – 20); in contrast, M2-type TAMs induced by macrophage colony-stimulating factor (M-CSF), IL-4, IL-10, IL-13, transforming growth factor…”
InfluentialCell-Based Therapies for Solid Tumors: Challenges and Advances
Smolarska, A., Kokoszka, Z., Naliwajko, M., Strupczewska, J., Tondera, J., Wiater, M., & Orzechowska, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125524 · Cited by 18
“Specifically, programmed cell death protein 1 (PD-1) expressed on activated T cells binds to its ligand PD-L1, which is often overexpressed by tumor-associated macrophages (TAMs) and other cells in the TME [124].”
Gou, Q., Liu, Z., Xie, Y., Deng, Y., Ma, J., Li, J., & Zheng, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.995555 · Cited by 17
“Correlation analysis between TIDE results members and TRG score showed that TRG score was highly positively correlated with CAFs, TAM M2, and MDSC, and all of these cells were reported to be immune suppressive cells and closely associated with cancer stemness (Kwak et al., 2020; Boutilier and Elsawa, 2021; Mao et al.,…”
ResultChettab, K., Fitzsimmons, C., Novikov, A., Denis, M., Phelip, C., Mathé, D., Choffour, P., Beaumel, S., Fourmaux, E., Norca, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1066402 · Cited by 18
“The impact of F2Lipo-MP-LPS on macrophages polarization must contribute to its potent antitumor effects as M1 macrophages are historically regarded as being antitumoral, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer thro…”
BackgroundLi, L., Ma, S., & Yu, Z. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00881-y · Cited by 17
Xie, S., Li, X., Jia, Y., Yu, H. J., Chen, S., & Chen, K. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1146 · Cited by 18
“8,40,41 M2 shows a distinct secretory profile, which leads to the low level of IL ‐ 12 and high levels of TGF ‐ β and IL ‐ 10, thereby promoting the anti ‐ inflammatory/protumorigenic responses.”
BackgroundTan, Z., Sheng, B., Chen, L., Dong, H., Deng, Y., Li, Y., Liu, C., Wang, H., Yang, Z., Xie, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1689114 · Cited by 17
“M1-like TAMs are induced by microbial products or IFN-g , enhancing antigen presentation and cytotoxicity via TNF-a , IL-12, and IL-1 b secretion (22 – 24).”
Yang, Y.-M., Ding, Y.-F., Hu, Y.-Y., Fan, F., & Zhao, J.-L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1723270 · Cited by 18
Nanoparticle-based non-viral CRISPR delivery for enhanced immunotherapy
Shin, H., & Kim, J. (2022) · Chemical Communications · doi:10.1039/d1cc05999h · Cited by 14
Ge, M., Shi, Y., & Liu, D. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221099460 · Cited by 14
Zhang, Y.-Y., Li, J., Li, F., Xue, S., Xu, Q., Zhang, Y., & Feng, L. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04655-9 · Cited by 17
“IL-10, and CD163 (Boutilier and Elsawa 2021; Mantovani et al.”
BackgroundShang, T., Yu, X., Gu, Y., Du, R., Cai, Y., Li, Y., Zheng, G., Wang, C., Zhang, J., Liu, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126539 · Cited by 14
Role of exosomes in metastasis and therapeutic resistance in esophageal cancer
Ning, X.-Y., Ma, J., He, W., & Ma, J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i42.5699 · Cited by 14
“Myeloid-derived suppressor cells (MDSCs) can suppress various types of immune responses and participate in the formation of the premetastatic niche and are immature myeloid cells closely linked to tumor development and prognosis [74,75].”
Association of Cutibacterium acnes with human thyroid cancer
Trivedi, V., Noronha, V., Sreekanthreddy, P., Desai, S., Poojary, D., Varghese, L., Gowda, P., Butle, A. B., Mishra, R., Bal, M. M., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1152514 · Cited by 14
“Also, M2 Macrophages (p = 0.8), act as anti-in fl ammatory, exhibits immune suppressive effect by lowering the antigen presenting capacity (27), tends to be higher in Cutibacterium high burden group is suggestive of reducing the immune response generation.”
BackgroundInfluentialLiu, R. D., Meng, X. Y., Li, C. L., Xu, Q. Y., Lin, X. Z., Dong, B. R., Ye, C. Y., Tian, M., Si, X. Y., Long, S. R., et al. (2023) · Parasites & Vectors · doi:10.1186/s13071-023-06051-1 · Cited by 15
“Additionally, M1-type macrophages secret pro-inflammatory cytokines, including IL-6, IL-1β and TNF-α, which can attract neutrophils, eosinophils and T cells, modulating the immune response [48].”
BackgroundAngelopoulou, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105414 · Cited by 14
“The tumor growth in the case of M12mac25 cells was probably attributed to the cell signaling mediated by the presence of tumor-associated macrophages that can activate pro-tumorigenic signaling pathways [96,97].”
BackgroundBibas, M., Castillo, J. J., & Sarosiek, S. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.061 · Cited by 20
“Recent findings have highlighted the important role of mast cells, T-cells, monocytes, and endothelial cells in the development of WM. 87 An excessive proliferation of mast cells distinguishes WM from MZL.”
BackgroundPath to bacteriotherapy: From bacterial engineering to therapeutic perspectives
Liu, J., He, C., Tan, W., & Zheng, J. H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122897 · Cited by 15
Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis
Shi, Z., Zhou, M., Zhai, J., Sun, J., & Wang, X. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400192 · Cited by 14
M1 macrophages as promising agents for cell therapy of endometriosis
Artemova, D. A., Vishnyakova, P., Elchaninov, A. V., Gantsova, E. A., Sukhikh, G. T., & Fatkhudinov, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36340 · Cited by 16
3D‐Printed Breast Prosthesis that Smartly Senses and Targets Breast Cancer Relapse
Wang, L., Ye, C., Xue, X., Xie, M., Zhi, Y., Feng, X. N., Zhao, P., Zhou, J., Mi, M., Li, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202402345 · Cited by 15
Guan, H., Tao, H., Luo, J., Wan, L., Hu, H., Chen, L., Wen, Z., Tao, Y., Chen, S., & Gu, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05222-1 · Cited by 15
“M2 macrophages are known to secrete a variety of cytokines and chemokines, including IL-10, TGF-β, and VEGF, which are critical in promoting tumor progression and inhibiting immune cell-mediated killing [6].”
Zhang, F., Jozani, K. A., Chakravarty, A., Lin, D. S. Y., Hollinger, A., Rajasekar, S., & Zhang, B. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202402946 · Cited by 16
Nanoimmunotherapy: the smart trooper for cancer therapy
Parveen, S., Konde, D. V., Paikray, S. K., Tripathy, N. S., Sahoo, L., Samal, H. B., & Dilnawaz, F. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002308 · Cited by 15
Extracellular PKM2 modulates cancer immunity by regulating macrophage polarity
Peng, G., Li, B., Han, H., Yuan, Y., Mishra, F., Huang, Y., & Liu, Z. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04050-y · Cited by 15
“However, TAMs in late-stage cancer are predominately M2 subtype [8, 9].”
Tao, H., Chen, D., Yang, C., Nguyen, D., Abboud, G., Liu, R., Liu, T., Chakraborty, A., Hou, A. Y., Petit, N. A., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184043 · Cited by 18
“M1-M Φ are reported to be proinflammatory and antitum-origenic, while M2-like M Φ , often presented as TAMs or M2-like M Φ , are antiinflammatory and protumorigenic (58, 59).”
Liu, Z., Zhang, J., Hong, L., Nie, Q., & Sun, X. (2025) · Science Advances · doi:10.1126/sciadv.adv3316 · Cited by 16
“TAMs can generally be divided into antitumorigenic (M1) macrophages and protumorigenic (M2) macrophages, which can polarize into each other within the tumor microenvironment (TME) ( 6 ).”
InfluentialQin, J., Dai, W.-B., Zhang, W., Chen, B., Liang, L., Liang, C., Lu, C.-C., Tan, Q., Wei, C., Tan, Y., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14664-1 · Cited by 14
“Numerous studies have demonstrated that M2-type TAMs secrete a variety of prometastatic factors, directly enhancing tumor invasion and metastasis [39].”
Inducing ferroptosis to improve cancer therapy: a promising tool for enhancing immunotherapy
Caforio, M., Iacovelli, S., Locatelli, F., & Folgiero, V. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03593-3 · Cited by 18
“Another important role exerted by HIF-1 concerns the recruitment of macrophages, also driving them into M2 polarization, acquiring immunosuppression property [99, 100], as they have gained the ability to inhibit the activation of T-cells and DCs [101].”
Role of macrophages in progression of colorectal cancer: a contrast with the traditional paradigm.
Konstantinov, A., Kovaleva, O. V., Samoilova, D. V., & Shelekhova, K. V. (2022) · PubMed · Cited by 23
Multifunctional immunotherapeutic gel prevented postoperative recurrence of hepatocellular carcinoma
Hu, Y., Chen, L., Liu, M., Ma, Z., Zhou, C., Yao, Z., Zhang, S., Song, C., Wang, Z., Zhu, X., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.141124 · Cited by 14
Interpreting Iron Homeostasis in Congenital and Acquired Disorders
Scaramellini, N., Fischer, D. P., Agarvas, A. R., Motta, I., Muckenthaler, M. U., & Mertens, C. (2023) · Pharmaceuticals · doi:10.3390/ph16030329 · Cited by 19
An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
Ferrarini, I., Bernardelli, A., Lovato, E., Schena, A., Krampera, M., & Visco, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1149616 · Cited by 15
“Historically, macrophages have been functionally clustered into two forms, known as M1 and M2 (14).”
BackgroundXiao, Y., Zhou, H., Chen, Y., Liu, L., Wu, Q., Li, H., Lin, P., Li, J., Wu, J., & Tang, L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1186862 · Cited by 15
“, 2019; Guillerey, 2020; Lees, 2020), while M1 macrophages were previously thought to have anti-tumor effects (Boutilier and Elsawa, 2021; Gunassekaran et al., 2021).”
BackgroundGong, Q., Li, H., Song, J., & Lin, C. (2023) · Journal of Cancer · doi:10.7150/jca.83466 · Cited by 14
“M1 macrophages exhibit pro-inflammatory properties through highly efficient antigen presentation [13, 14], whereas M2 macrophages have anti-inflammatory properties owing to their poor ability to present antigens and are related to immune tolerance [15, 16].”
BackgroundLiu, Y., Zheng, H., Gu, A. M., Li, Y., Wang, T., Li, C., Gu, Y., Lin, J., & Ding, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310625 · Cited by 15
Sun, Z., Chu, Y., Xiao, J., Yang, Y., Meng, F., Wang, X., Dong, Y., Zhu, J., Wu, Y., Qin, L., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04504-w · Cited by 15
“Tumor associated macrophages were polarized from M2-like phenotype into M1-like phenotype, indicating the triple vaccine changed the tumor microenvironment from immunosuppressive to immunostimulatory state [45, 46].”
BackgroundZHANG, Y., TANG, S., GAO, Y., LU, Z., Yang, Y., Chen, J., & Li, T. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.043481 · Cited by 14
Contemporary Approaches to Immunotherapy of Solid Tumors
Kuznetsova, A. V., Glukhova, K. А., Попова, О. П., Beletsky, I. P., & Aa, I. (2024) · Cancers · doi:10.3390/cancers16122270 · Cited by 14
“TAMs located also at the tumor periphery are thought to impede the entry of CTLs into the tumor core [5,41,42].”
BackgroundThe tumor microenvironment: adding pieces to the puzzle
Aguilar‐Cázares, D., Perez-Medina, M., Benito-Lopez, J. J., Galicia-Velasco, M., Meneses-Flores, M., Camarena, Á., & López-González, J. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1731338 · Cited by 16
“In advanced cancer stages, these subsets preferentially in fi ltrate speci fi c tumor niches (72, 73).”
Bao, W., Qu, X., Wang, Y., Huang, D., Zhang, H., Dong, M., Sun, H., Yang, Z., & Li, X. (2026) · MedComm · doi:10.1002/mco2.70599 · Cited by 15
“Monoclonal antibodies and small-molecule inhibitors targeting CSF1R have demonstrated significant reductions in TAMs abundance alongside increased CD8 + /CD4 + T cell ratios [ 324 ] (Figure 6A ).”
Li, Y., Li, R., Qin, H., He, H., & Li, S. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110835 · Cited by 13
Khanduri, I., Maru, D. M., & Parra, E. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223864 · Cited by 17
Copine 1 predicts poor clinical outcomes by promoting M2 macrophage activation in ovarian cancer
Sheng, B., Zhao, B., Dong, Y., Zhang, J., Wu, S., Ji, H., & Zhu, X. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad067 · Cited by 13
“M2 macrophages are tumour promoting, while M1 macrophages are proinflammatory and are identified as anti-tumour (41).”
BackgroundTargeting the adenosine signaling pathway in macrophages for cancer immunotherapy
Han, Y., Zhang, Z., Zhao, K., Zhang, Y., Yin, X., Zhu, G., Wang, Z., Yan, X., Li, X., He, T., et al. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110774 · Cited by 14
Non-targeted effects of radiation therapy for glioblastoma
Lerouge, L., Ruch, A., Pierson, J., Thomas, N., & Barberi‐Heyob, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30813 · Cited by 13
“Furthermore, it has been suggested that the immunostimulatory effects of radiotherapy are mediated by modulation of polarized microglia/macrophages; M2 type increases tumor growth and suppresses immune responses, whereas M1 type reduces tumor growth [21 – 23].”
BackgroundTumor microenvironment: A playground for cells from multiple diverse origins
Bharadwaj, D., & Mandal, M. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189158 · Cited by 15
Qin, X., Niu, R., Tan, Y., Huang, Y., Ren, W., Zhou, W., Wu, H., Zhang, J., Xu, M., Zhou, X., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00685-8 · Cited by 17
“Recently, the exosomes in blood, saliva or urine from patients suffering from different cancers have been frequently reported to be liquid biopsy sources for cancer detection [40, 41, 42].”
Chen, X., Zhang, Z., & Wang, K. (2025) · Genes & Genomics · doi:10.1007/s13258-025-01622-1 · Cited by 15
“Lactate and LDHA also contribute to the TME and macrophage polarization in LUAD (Shang et al. 2022a, b).”
Zhao, W. K., Wu, Y., Wang, Y., Li, T., Liu, Q., & Hou, Z. (2025) · Medical Oncology · doi:10.1007/s12032-025-02635-2 · Cited by 15
“The M1 and M2 designations reflect the cells' activation status and associated functions [10].”
Lü, J., Zhou, Y., Song, Y., Wang, J., & Xian, J.-X. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156709 · Cited by 15
SOCS3: An Immunological Biomarker Offering Potential Therapeutic Targets for Malignant Tumors
Zhang, Y., Chu, M., Ye, M., Yin, Y., & Chen, H. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00296-z · Cited by 14
“The TME is a highly complex system comprising tumor cells, infiltrating immune cells (such as macrophages [100], dendritic cells [101], and lymphocytes [102]), cancer-associated stromal cells (e.g., cancer-associated fibroblasts [103]), the extracellular matrix [104], and various signaling…”
Busà, R., Bulati, M., Badami, E., Zito, G., Maresca, D. C., Conaldi, P. G., Ercolano, G., & Ianaro, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.907572 · Cited by 15
“In particular, different studies support the hypothesis that tumor-promoting macrophages have a M2-like phenotype (Mantovani et al., 2002; Boutilier and Elsawa, 2021), while the M1-like one is associated with anti-tumor properties (Noy and Pollard, 2014; Ubil et al., 2018; Wanderley et al., 2018).”
ResultTargeting IL-34/MCSF-1R Axis in Colon Cancer
Monteleone, G., Maresca, C., Colella, M., Pacifico, T., Congiu, D., Troncone, E., & Marafini, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.917955 · Cited by 13
miR-aculous new avenues for cancer immunotherapy
Tang, W. W., Bauer, K. M., Barba, C., Ekiz, H. A., & O’Connell, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929677 · Cited by 15
Kassouri, C., Torres, S. R., Suárez, N. G., Duhamel, S., & Annabi, B. (2022) · Cancers · doi:10.3390/cancers14205065 · Cited by 14
“As a result of their enhanced antitumor inflammatory responses, M1 phenotype macrophages are resistant to tumours [36], whereas M2 macrophages, also known as TAM, are endowed with a variety of tumorpromoting abilities including, among others, immuno-suppression, angiogenesi , as well as stromal activation and remodeli…”
BackgroundRadioimmunoconjugates in the age of modern immuno-oncology
Nasr, D., Kumar, P. A., Zerdan, M. B., Ghelani, G. H., Dutta, D., Graziano, S. L., & Lim, S. H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121126 · Cited by 13
Schuller, A. A., Abushukair, H. M., Cavalcante, L. L., Hentzen, S., Saeed, A., & Saeed, A. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44110390 · Cited by 13
“The interaction between growth factor CSF-1 and its receptor CSF-1R is another key pathway in the recruitment of macrophages and their polarization to M2 [69].”
BackgroundAn Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis
Yan, H., Zhang, J.-L., Leung, K. T., Lo, K. W., Yu, J. Q., To, K., & Kang, W. (2023) · Cancers · doi:10.3390/cancers15030736 · Cited by 18
Du, J., Su, Y., Wang, R., Dong, E., Cao, Y., Zhao, W., & Gong, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118378 · Cited by 15
Yang, L., Zhang, Z., & Wang, L. (2023) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12651 · Cited by 13
“phages, the most two common macrophages, among which M1 macrophages are believed to have anti-inflammatory function while M2 macrophages are regarded as tumor contributors.(5) M2 like TAMs,”
BackgroundZhou, C., Chen, J., Zheng, B., Zhu, P., Chu, Q., Li, F., Fu, Y., Li, X., & Luo, J. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c08936 · Cited by 13
Yoo, Y. J., Eun, R., Park, H.-M., Kim, S., Park, S. H., Heo, J., & Lim, Y. T. (2023) · Small · doi:10.1002/smll.202307694 · Cited by 14
Wang, R., Zhang, S., Liu, Y., Li, H., Guan, S., Zhu, L., Jia, L., Liu, Z., & Xu, H. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156419 · Cited by 13
B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer
Zhang, H., Zhu, M., Zhao, A., Shi, T., & Xi, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189031 · Cited by 15
Zhang, M., Yu, L., Sun, Y., Hao, L., Bai, J., Yuan, X., Wu, R., Hong, M., Liu, P., Duan, X., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415603 · Cited by 15
Takeda, M., Akamatsu, S., Kita, Y., Goto, T., & Kobayashi, T. (2023) · Nanomaterials · doi:10.3390/nano13101611 · Cited by 12
“Macrophage polarization is one of the critical changes in the tumor microenvironment that favors cancer progression [89].”
BackgroundZeng, X., Huang, X., Yin, L., Yu, H., Wang, S., & Li, L. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.07.007 · Cited by 13
Prieto, Á. A., Díaz‐Rodríguez, P., Gómez, M. A. G., García‐Acevedo, P., Alves, L. D. C., Piñeiro, Y., & Rivas, J. M. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.11.004 · Cited by 11
Cheng, H., & Zheng, Y. (2024) · PeerJ · doi:10.7717/peerj.16825 · Cited by 13
“However, the classi fi cation of macrophages is not a simple binary differentiation of M1 and M2; in fact, the division between them is blurred, and more transitional subtypes exist ( Boutilier & Elsawa, 2021 ).”
BackgroundGao, J., Tan, W., Yuan, L., Wang, H., Wen, J., Sun, K., Chen, X., Wang, S., & Deng, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27220 · Cited by 14
Griffin, K. H., Mizenko, R. R., Arun, V., Carney, R. P., & Leach, J. K. (2024) · Advanced Biology · doi:10.1002/adbi.202300577 · Cited by 15
Liu, X., Zhang, Z., Yuan, J., Yu, J., & Chen, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1396719 · Cited by 13
“…treatment resistance (7 – 9).. Tumor-associated macrophages (TAMs) constitute a signi fi cant proportion of the tumor microenvironment, and many experimental and clinical studies have demonstrated their substantial correlation with tumor staging, invasion, metastasis, and drug resistance (10 – 13).”
BackgroundJeon, H. J., Lim, D., So, E., Kim, S., Jeong, J., Song, M., & Lee, H. J. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.011 · Cited by 13
Wang, J., Wang, Y., & Jiang, X. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2384071 · Cited by 14
“…can also expand angiogenesis and metastasis by releasing some chemoattractants for immunosuppressive cells and releasing pro-angiogenic molecules [119,120]. ctls are known as the central players in adaptive immunity against cancer cells. these cells play a vital role in antitumor immunity and…”
Kim, J. M., Yong, S. H., Jang, G., Kim, Y., Park, R., Koh, H. H., Kim, S., Oh, C., & Lee, S. H. (2024) · Communications Biology · doi:10.1038/s42003-024-06568-w · Cited by 18
“GSEAandssGSEAforimmunecellsubtypeswere performedusingthesemarkers 23 – 26 .”
Chen, D., Tong, W., Ang, B., Bai, Y., Dong, W., Deng, X., Wang, C., & Zhang, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12861-y · Cited by 14
“The M2 macrophages were characterized by C1QC, CD163, and CD206(MRC1) expression, markers of M2 TAM [27, 28].”
BackgroundZhou, B., Qin, Q., Fang, Y., Liu, X., Zhang, M., Wang, S., Zhong, L., & Guo, R. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123108 · Cited by 14
Zhang, L., Chen, J., Liu, Y.-X., Zhang, Y., Hong, L., Li, X., Liu, S., Chen, S., Peng, L., & Huang, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1341056 · Cited by 14
Yuan, W., Sun, Q., Zhu, X., Li, B., Zou, Y., & Liu, Z. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12060 · Cited by 13
Liang, H., & Zhang, S. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01668-5 · Cited by 14
“TAMs, especially M2-polarized macrophages, are prevalent in the TME and exhibit pro-tumorigenic properties [9].”
Liu, B., Peng, Y., Wang, C., Wei, H., Xu, S., Liu, Y., Yin, X., Bi, H., & Guo, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-01286-7 · Cited by 12
Xu, J.-L., Mo, J., Jiang, Y., Yang, T., Lu, Z., Liu, H., Ding, J., Shi, F., & Liu, R. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115009 · Cited by 16
Hou, Y., Zhao, T., Guo, Y., & Shi, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152489 · Cited by 14
Gong, L., Li, S., Sun, J., Liu, R., Wang, J., Wang, S., Zhao, Y., Yan, L., Ji, M., Yang, D., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123651 · Cited by 14
Polyamines in pancreatic cancer: reshaping the immunosuppressive tumor microenvironment
Jiang, S., Ren, B., Ding, C., Du, C., Cao, Z., Yang, G., Huang, H., & Zhang, T. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218016 · Cited by 17
Mitochondrial lipid metabolism in tumor immunosurveillance and evasion
Plata-Gómez, A. B., Chen, W., Ho, P., & Ling, G. S. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.08.005 · Cited by 17
Macrophage Phenotypic Switch and Obesity‐Associated Metabolic Risk: Mechanisms and Targets
Vera, K., Hemakumar, C., Bilachi, R. S., Ramírez, D. C., & Gomez-Mejiba, S. (2025) · Oxidative Medicine and Cellular Longevity · doi:10.1155/omcl/6710641 · Cited by 16
“C motif chemokine ligand 13 (CXCL13); the growth factors TGF β and vascular endothelial growth factor (VEGF); and other components involved in humoral immunity, wound healing and tolerance of autoantigens and neoantigens [28 – 30].”
Qian, Z., Zhang, Z., Bai, W., Li, J., Rao, X., Huang, G., Liu, J., & Wei, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1628142 · Cited by 13
“In contrast, M2 macrophages, induced by IL-4, IL-13, IL-10, or glucocorticoids, produce anti-in fl ammatory cytokines, primarily TGF-b and IL-10 (90).”
The paradigm-shifting roles of caspase-3 in cancer: from death towards resuscitation
Feng, X., Wang, Y.-W., He, S., & Huang, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04179-5 · Cited by 15
“In tumor microenvironment, tumor-associated macrophages (TAMs) are one of the various immune cell types and generally categorized into two functionally contrasting subtypes [119].”
Yin, R., Zhai, X., Han, H., Tong, X., Li, Y., & Deng, K. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.608 · Cited by 14
Koukourakis, I. M., Platoni, K., TINIAKOS, D. G., Kouloulias, V., & Zygogianni, A. G. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45050285 · Cited by 13
“As tumor-associated macrophages (TAMs) can be polarized towards M1-effector or M2-immunosuppressive phenotype, their role in response to RT and prognosis may be differentially driven by the TAM-subtype prevalence [89].”
BackgroundEffects of tramadol via a µ-opioid receptor on pancreatic ductal adenocarcinoma in vitro and in vivo
Kuramochi, T., Sano, M., Kajiwara, I., Oshima, Y., Itaya, T., Kim, J., Ichimaru, Y., Kitajima, O., Masamune, A., Ijichi, H., et al. (2023) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2023-104511 · Cited by 12
Metadata
- Authors
- Boutilier, A. J., & Elsawa, S. F.
- Affiliations
- University of New Hampshire (US)
- Corresponding author
- Elsawa, Sherine F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-29
- Volume
- 22
- Issue
- 13
- Pages
- 6995
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8268869
- OpenAlex
- W3173665490
- Cited by
- 1,631
- References
- 148
- Citations by year
- 2026: 281 · 2025: 409 · 2024: 429 · 2023: 359 · 2022: 144 · 2021: 9
- FWCI
- 24.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (P20 GM113131)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- macrophage polarization, tumor-associated macrophages, tumor microenvironment, tumor progression, angiogenesis, lymphangiogenesis, immunosuppression, hypoxia, metastasis, macrophage recruitment
- MeSH terms
- Tumor-Associated Macrophages, Animals, Hypoxia, Cell Transformation, Neoplastic, Humans, Inflammation, Macrophage Activation, Neoplasm Metastasis, Neoplasm Staging, Signal Transduction, Biomarkers, Immunophenotyping, Cytokines, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.